Aurobindo Pharma Limited — JV/Acquisition, 30-07-2025: Acquisition

Aurobindo Pharma's US subsidiary is acquiring 100% of Lannett Company LLC for US$250 million (INR 21,850 Cr). This strategic move significantly expands Aurobindo's US manufacturing footprint, adding a 425k sq ft facility with ~3.6 billion doses capacity. Lannett brings a strong portfolio of complex generics, especially non-opioid controlled substances (ADHD treatments) and liquids, plus a growing CDMO business. This acquisition strengthens Aurobindo's presence in high-value therapeutic areas, leverages domestic capabilities, provides substantial growth capacity, and is expected to boost earnings.